Search research articles
Contact Us
Filters
Showing results (171-180 of 184) with videos related to
Page
of 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
ESMO Open
|
January 4, 2025
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
A Gravina, P Gargiulo, M De Laurentiis, et al.
Journal of Endocrinological Investigation
|
June 27, 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view
A Natalicchio, N Marrano, M Montagnani, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2014
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
F Perrone, F Nuzzo, F Di Rella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
S Pignata, D Califano, D Lorusso, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2012
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
F Nuzzo, C Gallo, S Lastoria, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 184) with videos related to
Sort By:
Page
of 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
ESMO Open
|
January 4, 2025
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
A Gravina, P Gargiulo, M De Laurentiis, et al.
Journal of Endocrinological Investigation
|
June 27, 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view
A Natalicchio, N Marrano, M Montagnani, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2014
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
F Perrone, F Nuzzo, F Di Rella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
S Pignata, D Califano, D Lorusso, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2012
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
F Nuzzo, C Gallo, S Lastoria, et al.
Page
of 19